Role of receptor tyrosine kinase AXL in tumor drug resistance
10.3969/j.issn.1674-8115.2018.07.020
- Author:
Yi-Peng ZHANG
1
Author Information
1. Shanghai Jiao Tong University College of Basic Medical Sciences
- Publication Type:Journal Article
- Keywords:
AXL;
Drug resistance;
Epithelial-mesenchymal transition;
Prognosis;
Receptor tyrosine kinase;
Small molecule inhibitor;
Tumor
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(7):819-824
- CountryChina
- Language:Chinese
-
Abstract:
AXL is a member of TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which is overexpressed in many cancers, including nonsmall cell lung cancer, breast cancer and ovarian cancer. It can mediate the occurrence of epithelial-mesenchymal transition, and plays an important role in tumor drug resistance. In addition, AXL can also mediate the occurrence of targeted agents resistance by regulating the signaling pathway and influencing tumor microenviroment. As a result, AXL is an attractive candidate not only as a prognostic indicator in malignancy but also as a target for anti-cancer therapy. Several multi-target small molecule inhibitors against AXL have been approved, and varieties of inhibitors with higher specificity are in clinical or preclinical studies. This article focused on the role of AXL in tumor drug resistance and summarized the research profiles of different small molecule inhibitors against AXL to provide new ideas for anti-tumor research and therapy.
